Skip to content
Finance & Wealth

Are the Sacklers Still Rich?

In this article

Yes, the Sackler family remains extraordinarily wealthy. Despite the multi-billion dollar settlement agreements related to the Purdue Pharma bankruptcy and the opioid crisis, the family’s collective net worth is estimated to remain in the billions. This is due to years of profit-taking from Purdue Pharma and diversified international investments that were shielded from the initial bankruptcy proceedings.

The question of whether the Sackler family is still rich is not just a matter of bank balances; it is a complex intersection of corporate law, bankruptcy proceedings, and international finance. As of 2026, the family remains among the wealthiest dynasties in the world, even as their public reputation has undergone a total collapse. To understand how they maintained this wealth, one must look at the mechanics of the Purdue Pharma bankruptcy, the 2024 Supreme Court ruling, and the family’s global investment strategies.

The Financial Foundation of the Sackler Fortune

The wealth of the Sackler family was primarily built through Purdue Pharma, the company responsible for the development and aggressive marketing of OxyContin. While the Sackler brothers (Arthur, Mortimer, and Raymond) had various business interests, it was the 1996 launch of the long-acting opioid that transformed them from successful pharmaceutical executives into global billionaires.

The OxyContin Era and Purdue Pharma

During the peak years of OxyContin sales, Purdue Pharma generated tens of billions of dollars in revenue. Financial records revealed during legal proceedings showed that the family withdrew more than $10 billion from the company between 2008 and 2017. These distributions occurred as the company faced increasing legal scrutiny regarding its marketing practices and the resulting opioid epidemic.

By the time Purdue Pharma filed for Chapter 11 bankruptcy in 2019, much of the family’s personal wealth had already been transferred out of the company. This strategy proved critical for their financial survival. Because the money was held in private trusts and offshore accounts, it was not technically part of the Purdue Pharma corporate estate, making it significantly harder for plaintiffs to seize.

Diversification and Global Holdings

The Sackler wealth is not tied solely to the American pharmaceutical market. A significant portion of their assets is managed through Mundipharma, an international network of independent associated companies. While Purdue Pharma operated primarily in the United States, Mundipharma sold OxyContin and other products in Europe, Asia, and Latin America.

By diversifying their holdings across different jurisdictions, the Sackler family created a financial "moat." Even as Purdue Pharma was dismantled in the U.S. court system, their international operations continued to generate revenue and provide a buffer against domestic legal liabilities.

Quantifying the Sackler Wealth in 2026

Determining the exact net worth of the Sackler family in 2026 is challenging due to the private nature of their holdings. However, analysts and investigative journalists have provided estimates based on court filings and public records.

Before the major legal settlements began, the family’s net worth was often estimated between $13 billion and $15 billion. While they have committed to paying billions in settlements, these payments are typically structured over a decade or more.

Financial Metric Estimated Value (Pre-Settlement) Current Status (2026)
Total Family Net Worth $13 - $15 Billion Estimated $8 - $11 Billion
Purdue Pharma Assets $1 - $2 Billion Liquidated/Consolidated into Knoa Pharma
Offshore/Diversified Assets $10+ Billion Primarily Intact
Real Estate & Art $500 - $800 Million Partial Liquidations Reported
Settlement Obligations $0 ~$6 Billion (Paid over 18 years)

The Impact of the $6 Billion Settlement

The most significant drain on the Sackler fortune has been the negotiated settlement associated with the Purdue Pharma bankruptcy. Under the terms discussed and refined through various court challenges, the Sackler family agreed to pay up to $6 billion to address the damages caused by the opioid crisis.

Crucially, this $6 billion is not paid in a single lump sum. The payments are staggered over nearly two decades. Because the family continues to earn interest and investment returns on their remaining billions, the "real" cost of the settlement is mitigated by the time value of money. For a family with $10 billion in diversified assets, an annual payment of a few hundred million dollars can often be covered by investment growth alone, leaving the principal fortune largely untouched.

Ep. #145 - Why Rich People Still Feel Poor | Haas Financial Group
Ep. #145 - Why Rich People Still Feel Poor | Haas Financial Group

The 2024 Supreme Court Ruling and Its Aftermath

A pivotal moment in the family's financial history occurred in June 2024. The U.S. Supreme Court, in the case of Harrington v. Purdue Pharma L.P., rejected the original bankruptcy plan. The Court ruled that the bankruptcy code does not allow for "non-consensual third-party releases."

What This Meant for the Sackler Fortune

This ruling was a double-edged sword for the family's wealth:

  1. Loss of Immunity: The original deal would have granted the Sackler family permanent immunity from all future civil lawsuits related to the opioid crisis. The Supreme Court ruling stripped this protection away, meaning the family could, in theory, be sued individually by thousands of victims and local governments.
  2. Negotiation Leverage: Because the ruling threatened to blow up the entire bankruptcy settlement—which victims and states desperately needed for treatment programs—it led to a new round of high-stakes negotiations.

As of 2026, the legal landscape has shifted toward a modified agreement where the family pays a higher premium in exchange for more robust releases, or they face the "death by a thousand cuts" of individual litigation. Despite these legal headwinds, the family has remained "rich" because the vast majority of their assets remain in jurisdictions or trust structures that are extremely difficult for U.S. plaintiffs to reach.

Where is the Money Now?

The Sackler wealth in 2026 is characterized by its liquidity and internationality. Unlike other billionaire families whose wealth is tied to a single public stock, the Sacklers have converted much of their pharmaceutical equity into cash, bonds, and diversified private equity.

Real Estate Holdings

The family has historically owned a vast portfolio of high-end real estate, including:

  • Luxury apartments on Manhattan’s Upper East Side.
  • Sprawling estates in the Hamptons and Connecticut.
  • High-value properties in London and the Swiss Alps.

While some of these properties have been sold to help fund legal costs or settle debts, the family remains ensconced in some of the most expensive ZIP codes in the world. These physical assets provide both a lifestyle of extreme luxury and a store of value that is resistant to market volatility.

The Art Collection

The Sacklers were once among the world’s most prominent art collectors and patrons. While their names have been removed from the walls of the Metropolitan Museum of Art, the Louvre, and the British Museum, the family still owns a significant private collection of ancient and contemporary art. High-value art functions as a portable, high-value asset class that can be sold at auction when liquid capital is required.

The Social and Cultural Devaluation

While the Sacklers remain financially rich, they have suffered an unprecedented loss of "social capital." In the world of the ultra-wealthy, the ability to influence cultural institutions is often as important as net worth.

  • Stripping of Names: Museums and universities worldwide have removed the Sackler name from galleries and wings.
  • Philanthropic Rejection: Major charitable organizations have publicly stated they will no longer accept donations from the family.
  • Social Ostracization: Many family members have retreated from public life, moving to more private enclaves or shifting their primary residence to European cities where the public outcry is less concentrated than in the United States.

For the Sacklers, being "rich" in 2026 means living in a golden cage—possessing the means to buy almost anything, but losing the ability to buy back the prestige they once enjoyed.

Frequently Asked Questions

Did the Sacklers lose all their money in the lawsuits?

No. While they have committed billions of dollars to settlements, these payments represent only a portion of their total wealth. Because the payments are spread out over many years, the family remains in the billionaire class.

Can the government seize their remaining assets?

Seizing assets is difficult, especially when they are held in offshore trusts or international accounts. The 2024 Supreme Court ruling opened the door for more civil lawsuits, but winning a judgment and actually collecting money from a complex global web of private trusts are two very different legal challenges.

Do the Sacklers still own Purdue Pharma?

Purdue Pharma as it once existed is gone. Under the bankruptcy plans, the company was dissolved or transitioned into a new entity (often referred to as Knoa Pharma) that is managed by a public benefit trust. The Sackler family no longer has any involvement in the management or profits of the successor company.

Are all members of the Sackler family equally wealthy?

The wealth is divided among several branches of the family, primarily the heirs of Mortimer and Raymond Sackler. The branch of Arthur Sackler (the eldest brother) sold its stake in Purdue Pharma shortly after his death in 1987, before OxyContin was developed. As a result, that branch has generally been less targeted by litigation, though they remain independently wealthy.

Where do the Sacklers live now?

Members of the family are spread across the globe. Many reside in the United Kingdom, Switzerland, and the United States. Their wealth allows them to maintain multiple residences and move between jurisdictions as legal or social pressures dictate.

Practical Considerations for Following the Case

For those tracking the financial status of the Sackler family or the distribution of opioid settlement funds, it is important to monitor official court registries and state attorney general reports.

  1. State Settlement Portals: Many U.S. states have created public dashboards to show how much money has been received from the Purdue/Sackler settlements and how it is being spent on addiction recovery.
  2. Bankruptcy Court Filings: The U.S. Bankruptcy Court for the Southern District of New York remains the primary repository for documents detailing the family's financial disclosures.
  3. Investigative Journalism: Outlets like The New Yorker and The New York Times continue to track the movement of the family's assets through investigative reporting.

The story of the Sackler wealth is a reminder that in the modern financial system, "rich" is a status that is very difficult to legally dismantle, even in the face of massive public and legal opposition.